CASI Pharmaceuticals, Inc. (CASI) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CASI Revenue Growth
Revenue Breakdown (FY 2019)
CASI's revenue distribution by segment and geography for fiscal year 2019
By Product/Segment
CASI Revenue Analysis (2013–2024)
As of May 6, 2026, CASI Pharmaceuticals, Inc. (CASI) generated trailing twelve-month (TTM) revenue of $26.8 million, reflecting significant decline in growth of -60.5% year-over-year. The most recent quarter (Q3 2025) recorded $3.1 million in revenue, down 26.3% sequentially.
Looking at the longer-term picture, CASI's 5-year compound annual growth rate (CAGR) stands at +47.2%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $43.1 million in 2022.
Revenue diversification analysis shows CASI's business is primarily driven by E V O M E L A (100%). With over half of revenue concentrated in E V O M E L A, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ZLAB (+15.3% YoY), LEGN (+64.2% YoY), and ZYME (+38.9% YoY), CASI has underperformed the peer group in terms of revenue growth. Compare CASI vs ZLAB →
CASI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CASICurrent | $27M | -60.5% | +47.2% | -138.8% | |
 ZLAB | $460M | +15.3% | +56.5% | -49.9% | |
 LEGN | $1.0B | +64.2% | +68.9% | -13.3% | |
 ZYME | $106M | +38.9% | +22.2% | -87.3% | |
 CAN | $530M | +96.8% | +50.5% | -21.2% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% |
CASI Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $28.5M | -15.8% | $11.1M | 39.1% | $-39,621,000 | -138.8% |
| 2023 | $33.9M | -21.4% | $20.1M | 59.2% | $-25,080,000 | -74.0% |
| 2022 | $43.1M | +42.9% | $27.3M | 63.3% | $-26,491,000 | -61.5% |
| 2021 | $30.2M | +99.2% | $17.6M | 58.4% | $-41,516,000 | -137.6% |
| 2020 | $15.1M | +266.5% | $5.6M | 37.2% | $-52,781,000 | -348.6% |
| 2019 | $4.1M | - | $196K | 4.7% | $-39,991,000 | -968.1% |
| 2018 | $0 | - | $-1,670,934 | - | $-26,504,446 | - |
| 2017 | $0 | - | $-117,779 | - | $-10,751,320 | - |
| 2016 | $0 | -100.0% | $-66,451 | - | $9.4M | - |
| 2015 | $48K | +101.1% | $41K | 86.9% | $7.2M | 14990.8% |
See CASI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CASI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CASI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCASI — Frequently Asked Questions
Quick answers to the most common questions about buying CASI stock.
Is CASI's revenue growth accelerating or slowing?
CASI revenue declined -60.5% year-over-year, contrasting with the 5-year CAGR of +47.2%. TTM revenue fell to $27M. This reverses the prior growth trend.
What is CASI's long-term revenue growth rate?
CASI Pharmaceuticals, Inc.'s 5-year revenue CAGR of +47.2% reflects the variable expansion pattern. Current YoY growth of -60.5% is below this long-term average.
How is CASI's revenue distributed by segment?
CASI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.